| Therapeutic | Nivolumab |
| Target | PDCD1 |
| Heavy Chain | QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSS |
| Light Chain | EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIK |
| 100% seqID Fv Structure | 5ggq [Fvs: HL], 5ggr [Fvs: AB, HL], 5wt9 [Fvs: HL] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 5ggq [Fvs: HL] |
| 100% seqID Structure | 5wt9 [Fvs: HL] |
| 100% seqID Structure | 5ggr [Fvs: AB, HL] |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G4 |
| Highest Clinical Trial (August '23) | Approved |
| Estimated Status (August '23) | Active |
| Recorded Developmental Technology | Medarex UltiMAb Mouse |
| INN Year Proposed | 2012 |
| INN Year Recommended | 2013 |
| Companies Involved | Aduro BioTech, AIO Studien gGmbH, Australian and New Zealand Urogenital and Prostate Cancer Group, Barbara Ann Karmanos Cancer Institute, Bavarian Nordic, Big Ten Cancer Research Consortium, Bristol-Myers Squibb, Canadian Cancer Trials Group, Celleron Therapeutics, Clatterbridge Cancer Centre NHS Foundation Trust, Clovis Oncology, Curie Institute, Daiichi Sankyo Company, Dana-Farber Cancer Institute, Duke University Medical Center, Eisai Inc, Eli Lilly, Emory University, European Thoracic Oncology Platform, Exelixis, Frontier Science foundation, Grupo Espanol Multidisciplinar de Melanoma, H. Lee Moffitt Cancer Center and Research Institute, Hellenic Genitourinary Cancer Group, Hoosier Cancer Research Network, HOVON Foundation, Incyte Corporation, Intergroupe Francophone de Cancerologie Thoracique, Janssen Biotech, Janssen Research & Development, Kansai Medical University, Kyoto Breast Cancer Research Network, M. D. Anderson Cancer Center, Massachusetts General Hospital, Medarex, Nantes University Hospital, National Cancer Center (Tokyo), National Cancer Centre (Singapore), National Cancer Institute (USA), Nektar Therapeutics, Neon Therapeutics, Netherlands Cancer Institute, Northwestern University, Ono Pharmaceutical, Pharmacyclics, PrECOG, Seattle Genetics, Sidney Kimmel Cancer Center, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Syneos Health, The University of Montreal Hospital Research Center, UNICANCER, University College London, University of Liverpool, University of Pittsburgh, University of Texas M. D. Anderson Cancer Center, Vanderbilt-Ingram Cancer Center, Zucero Therapeutics |
| Conditions Approved | Colorectal cancer, Gastric cancer, Head and neck cancer, Hodgkin's disease, Malignant melanoma, Non-small cell lung cancer, Renal cell carcinoma, Urogenital cancer, Liver cancer, Mesothelioma, Small cell lung cancer |
| Conditions Active | Bladder cancer, Fallopian tube cancer, Glioblastoma, Multiple myeloma, Oesophageal cancer, Ovarian cancer, Peritoneal cancer, Non-Hodgkin's lymphoma, Acute myeloid leukaemia, Adrenocortical carcinoma, Biliary cancer, Brain metastases, Breast cancer, Bronchopulmonary dysplasia, Cancer, Cervical cancer, Cholangiocarcinoma, Chronic lymphocytic leukaemia, CNS cancer, Diffuse large B cell lymphoma, Follicular lymphoma, Genitourinary disorders, Leucoplakia, Liver metastases, Meningeal carcinomatosis, Myelodysplastic syndromes, Nasopharyngeal cancer, Oropharyngeal cancer, Pancreatic cancer, Penile cancer, Prostate cancer, Soft tissue sarcoma, Solid tumours, Testicular cancer, Thyroid cancer, Uterine cancer, Uveal melanoma, Haematological malignancies, Lymphoma, Rectal cancer, Chronic myeloid leukaemia, Glioma, Hepatitis C, Sepsis |
| Conditions Discontinued | na |
| Notes | na |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
